Results · Apr-Jun 2026 · filed 12 Aug 2026
Bliss GVS Pharma Q1 FY27 results
Sales grew 38% to ₹286 crore from ₹207 crore in Apr-Jun 2025.
Operating profit grew 85% to ₹76.4 crore, an operating margin of 26.8% (up 6.8 points from a year ago).
Net profit grew 16% to ₹51.4 crore from ₹44.4 crore in Apr-Jun 2025.
Against Jan-Mar 2026: sales +11%, net profit +39%.
Apr-Jun 2026 vs a year ago
| ₹ crore | Apr-Jun 2026 | Apr-Jun 2025 | Change |
|---|---|---|---|
| Sales | 285.6 | 207.5 | +38% |
| Operating profit (EBITDA) | 76.4 | 41.3 | +85% |
| Operating margin | 26.8% | 19.9% | +6.8 pts |
| Net profit | 51.4 | 44.4 | +16% |
Consolidated figures. Margins & ratios change in percentage points (pts).
The last 7 quarters
Filings that week
- 14 Aug 2026Announcement under Regulation 30 (LODR)-Newspaper Publication
- 12 Aug 2026Grant Of Options Under Bliss GVS Pharma Limited - Employee Stock Options Plan 2019
- 12 Aug 2026Outcome Of Board Meeting Held On Wednesday, August 12, 2026
- 12 Aug 2026Board Meeting Outcome for Outcome Of Board Meeting Held On Wednesday, August 12, 2026
- 11 Aug 2026Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS
- 11 Aug 2026Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
From the company's results filed on BSE (Consolidated). Business numbers only. Education & analysis, not investment advice or a recommendation.